tailieunhanh - Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

Novel antibody‒drug conjugates (ADC) have shown great efficacy in HER2-low advanced breast cancer. However, the clinical features of HER2-low disease still need to be clarified. The current study aims to evaluate the distribution and dynamic change in HER2 expression in patients with disease recurrence and the clinical outcome of those patients. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN